Management of Patients with Chronic Obstructive Pulmonary Disease (J40-J44)

Objectives

The guideline provides a clinical framework for lifelong management of chronic obstructive pulmonary disease (COPD), from identifying persistent airflow obstruction and risk factors to managing stable disease, exacerbations, complications and rehabilitation. Its principal aims are to improve quality of life, reduce exacerbations and symptoms, slow deterioration in lung function and maintain physical and work capacity.[1][2][3][4]

• Identify COPD through clinical presentation, examination and lung-function assessment, including spirometric measures of forced expiratory volume in one second, forced vital capacity and their ratio.[5][3]
• Classify disease by clinical stage and severity, ranging from early-risk or preclinical states to clinically manifest disease and disease with complications.[5]
• Reduce avoidable exposures, particularly active and passive smoking, polluted workplace or ambient air, and harmful household or occupational irritants.[5][6]
• Monitor disease progression, symptoms, treatment response and physical tolerance, while recognising worsening breathlessness, cough, sputum change and declining spirometry as signs of deterioration.[3]
• Manage stable disease and acute exacerbations through pharmacological treatment, rehabilitation, self-management education and oxygen therapy where clinically indicated.[3]
• Preserve or restore functioning through moderate physical activity, breathing control, healthy nutrition, family support and supervised follow-up.[6]
• Recognise severe respiratory deterioration and associated complications requiring urgent escalation, including respiratory arrest, severe hypoxaemia, hypercapnic acidosis, altered consciousness and cardiovascular collapse.[6]

Implementation

Care is principally organised through primary healthcare for continuing COPD management, supported by home or outpatient care, patient and family education, clinical monitoring and hospital escalation for severe exacerbations or complications. The guideline combines diagnostic assessment, severity-based treatment, rehabilitation and structured escalation to inpatient or intensified treatment when respiratory status deteriorates.[3][7][8][6]

• Assess patients using medical history, objective examination, spirometry where available, bronchodilator testing and chest radiography, with peak-flow measurement during each exacerbation and radiography at the second visit where described.[3]
• Select treatment according to severity, using bronchodilators, theophylline-based medicines, corticosteroids in specified circumstances and mucolytics; increase maintenance bronchodilation or add another bronchodilator group during exacerbations.[3][9][10]
• Provide antibacterial treatment for suspected infection for seven to ten days, with listed options including amoxicillin, erythromycin, co-amoxiclav, later-generation cephalosporins and fluoroquinolones.[4][10]
• Administer controlled oxygen therapy when oxygen saturation is below 88% by pulse oximetry or arterial oxygen partial pressure is below 55 mmHg, at two to three litres per minute as described.[10]
• Educate patients and families on the progressive nature of COPD, adherence to prescribed treatment, smoking cessation, medicine use and avoiding contact with people who have upper-respiratory viral or bacterial infections.[6]
• Deliver rehabilitation through appropriate exercise and breathing techniques, including diaphragmatic and pursed-lip breathing, controlled inhalation and prolonged exhalation, with gradual extension of practice.[11]
• Admit patients to hospital for severe exacerbation with breathlessness at rest, decompensated pulmonary heart disease, or serious coexisting illness, particularly among older people.[7]
• Manage severe inpatient exacerbations through intensified bronchodilation, nebulised treatment where appropriate, systemic corticosteroids, mucolytics, antibiotics when infection is present, controlled oxygen, fluid and nutrition monitoring, thromboembolism prevention and management of comorbidities.[12][8]
• Transfer patients to an intensified-treatment unit when severe breathlessness persists after emergency care, consciousness is impaired, or severe hypoxaemia, worsening hypercapnia or respiratory acidosis continues despite oxygen therapy and non-invasive ventilation.[8]
• Reassess oxygen saturation after 30 minutes of controlled oxygen therapy, evaluate bronchodilator effect after three to four hours, and monitor overall condition during treatment; expected clinical outcomes include resolution of exacerbation symptoms and stabilisation.[12][8]

Monitoring & Evaluation

Monitoring is primarily clinical and treatment-focused, covering disease progression, severity assessment, response to treatment and recognition of deterioration across primary, outpatient, home and hospital care. The extracts do not establish a formal programme-level monitoring and evaluation framework, surveillance system, reporting schedule, audit process, performance targets or named accountability body.[5][3][8][6]

• Assess chronic obstructive pulmonary disease through clinical history, objective examination, laboratory or instrumental investigations, and pulmonary-function testing.[5]
• Classify disease from early risk or preclinical stages to clinically manifest disease and disease with complications, using symptoms and measures of airway obstruction.[5]
• Measure forced expiratory volume in one second, forced vital capacity and their ratio to identify obstruction and grade disease severity, alongside symptoms such as chronic productive cough and breathlessness.[5]
• Monitor disease course and treatment response through symptoms, sputum characteristics, exercise tolerance and spirometry.[3]
• Identify worsening through increased breathlessness, more severe cough, purulent or increased sputum, lower physical tolerance and deteriorating spirometry findings.[3]
• Use peak-flow measurement during each exacerbation where applicable, undertake spirometry where feasible, consider bronchodilator testing, and use chest radiography at the second visit.[3]
• Assess severe exacerbations in hospital using clinical examination, respiratory and blood-gas measures, pulse-oximetry oxygen saturation and chest radiography.[8]
• Reassess oxygen saturation 30 minutes after controlled oxygen therapy and observe the patient’s overall condition continuously during treatment.[8]
• Evaluate bronchodilator effectiveness three to four hours after administration.[12]
• Recognise treatment response through resolution of exacerbation symptoms and stabilisation of the patient’s condition.[12][8]
• Monitor for pulmonary heart disease through signs including cyanosis, tachycardia, raised neck veins, hepatomegaly, peripheral oedema and an accentuated second pulmonary sound, supplemented by electrocardiography and echocardiography findings where available.[7]
• Escalate care for persistent severe breathlessness, impaired consciousness or coma, severe hypoxaemia, worsening hypercapnia or respiratory acidosis despite oxygen therapy and non-invasive ventilation.[8]
• Maintain clinical follow-up under medical supervision for people managed at home or in outpatient settings.[6]
• Track intended clinical outcomes, including improved quality of life, fewer exacerbations, slower deterioration in lung function and preservation of work capacity.[4]

Although the guideline uses numerous clinical measures and thresholds to guide individual care, it does not specify how facilities should aggregate results, report data to health authorities, compare performance, conduct periodic evaluations, or assign responsibility for meeting the stated outcomes.[5][3][4][8][6][11][13]

Costing & Financing

No costing or financing framework is specified. The extracts provide clinical resource requirements, including diagnostic tests, pulmonary-function assessment, radiography, pulse oximetry, blood-gas assessment, medicines, nebuliser treatment, controlled oxygen therapy, rehabilitation exercises and escalation to hospital or intensified treatment, but do not attach monetary values to these inputs.[3][12][8][6]

• Specify treatment durations for antibacterial therapy of 7 to 10 days, but provide no medicine prices, procurement costs or budget allocations.[4][10]
• Specify oxygen therapy at 2 to 3 litres per minute when indicated, but provide no oxygen-supply cost, equipment cost or funding source.[10]
• Describe home, outpatient, primary-care and inpatient management arrangements without identifying service budgets, reimbursement mechanisms, staffing costs or resource-mobilisation measures.[3][8][6]
• Omit funding gaps, donor or domestic financing sources, economic assumptions, affordability analysis and cost-effectiveness considerations.[9][10][8][6][11][13]